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Insulin resistanceEndothelin-1 (ET-1) is a vasoconstrictor, proinﬂammatory and proliferative endothelial cell-derived peptide
that is of signiﬁcant importance in the regulation of vascular function. It is involved in the development of
endothelial dysfunction including important interactions with nitric oxide. The expression and functional ef-
fects of ET-1 and its receptors are markedly altered during development of cardiovascular disease. Increased
production of ET-1 and its receptors mediate many pathophysiological events contributing to the develop-
ment of atherosclerosis and vascular complications in diabetes mellitus. The present review focuses on the
pathophysiological role of ET-1 and the potential importance of ET receptors as a therapeutic target for treat-
ment of these conditions.
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Endothelial dysfunction is considered to occur early during the de-
velopment of cardiovascular disease including atherosclerosis and
vascular complications associated with diabetes mellitus. A key
event in endothelial dysfunction is the reduction in bioavailability
and biological activity of nitric oxide (NO). Reduced levels of NOY-NC-ND license.contribute to increased vascular tone, inﬂammation, platelet aggrega-
tion and oxidative stress which all are central features of atheroscle-
rosis and diabetic vasculopathies (Versari et al., 2009). Development
of endothelial dysfunction involves several biological mediators in-
cluding increased expression of endothelin (ET)-1 and altered ex-
pression of ET receptors (Böhm and Pernow, 2007). Considering the
prominent biological actions mediated by ET-1 such as potent vaso-
constriction, pro-inﬂammatory actions and mitogenic properties,
overproduction of ET-1 may be of signiﬁcant pathological importance
in cardiovascular disease. The pathophysiological signiﬁcance of ET-1
508 J. Pernow et al. / Life Sciences 91 (2012) 507–516in pulmonary arterial hypertension is well characterized (Davie et al.,
2009). Recent data also indicate that ET-1 may be of importance for
the pathogenesis of atherosclerosis and vascular complications asso-
ciated with diabetes mellitus. Moreover, ET-1 may be involved in
the metabolic features of diabetes mellitus.
ET-1 production and secretion are primarily controlled at the gene
transcriptional level. ET-1 gene expression is regulated by a number
of transcription factors including activator protein 1 (AP-1), hypoxia
inducible factor-1, nuclear factor κB, vascular endothelial zinc ﬁnger
1 (Vezf1), GATA binding protein 2 (GATA-2) and GATA-4, nuclear fac-
tor of activated T-cells (NFAT) among others that are of relevance for
atherosclerosis and diabetes. The ET-1 gene regulation has been
reviewed in detail elsewhere (Stow et al., 2011). The transcription
factors are in turn activated by several inducers such as angiotensin
II, cytokines, glucose, insulin and hypoxia. Mature ET-1 is formed
from pre-pro-ET-1 via a 39-amino acid intermediate, big ET-1
(Kedzierski et al., 2003). Big ET-1 is processed to ET-1 by a family of
ET converting enzymes (ECEs) and other enzymes such as chymases,
non-ECE metalloproteinases and endopeptidases (Barton et al., 2003;
Kedzierski et al., 2003). Under physiological conditions, ET-1 is pro-
duced in small amounts mainly in endothelial cells, primarily acting
as an autocrine and/or paracrine mediator. Under pathophysiological
conditions, however, the production is stimulated in several cell types
such as endothelial cells, vascular smooth muscle cells, cardiac myo-
cytes (Ito et al., 1993) and inﬂammatory cells (Ehrenreich et al.,
1990; Sessa et al., 1991). Increased expression of ET-1 has been dem-
onstrated in atherosclerotic animal models (Barton et al., 1998;
Lerman et al., 1993) as well as in human coronary artery disease
(Lerman et al., 1991; Zeiher et al., 1994) and peripheral arterial dis-
ease (Böhm et al., 2002c). This results in enhanced vasoconstrictor
tone, increased inﬂammatory activity and elevated oxidative stress.
The effect of ET-1 is mediated via activation of its two distinct recep-
tors, the ETA and ETB receptors. In the vascular wall the ETA receptor is
localized to the smooth muscle cell and mediates the major part of
the vasoconstrictor effect of ET-1 under physiological conditions.
The ETB receptor is localized to the endothelial cells and mediates va-
sodilatation via release of NO. ETB receptors are also located on vascu-
lar smooth muscle cells and mediate vasoconstriction. However, as
pointed out below there is a substantial change in the expression
and function of the ET receptors in various pathophysiological condi-
tions resulting in an altered biological response. The present review
will focus on the pathophysiological role of ET-1 in atherosclerosis
and diabetes mellitus. The potential importance of ET receptors as a
therapeutic target for treatment of these conditions is also discussed.
Atherosclerosis
ET-1 in the vascular wall in atherosclerosis
Several studies have demonstrated increased expression of ET-1 in
experimental models of atherosclerosis as well as in human athero-
sclerosis (Barton et al., 1998; Lerman et al., 1993; Zeiher et al.,
1994). The increased expression is observed in cells normally ex-
pressing low levels of ET-1 such as vascular smooth muscle cells
and inﬂammatory cells. Thus, human vascular smooth muscle cells
harvested from human atherosclerotic coronary arteries express
higher amounts of ET-1 than cells from non-atherosclerotic arteries
(Haug et al., 1996). ET-1 is associated with regions of macrophage-
rich atherosclerotic plaques from patients with critical limb ischemia
(Dashwood and Tsui, 2010). Targeted endothelial cell overexpression
of ET-1 markedly increased atherosclerotic lesion size in apolipopro-
tein E gene deleted (apoE−/−) mice fed a high fat diet and the ex-
pression of lipid metabolism genes in comparison with wild type
mice (Simeone et al., 2010). This implies that increased endothelial
ET-1 expression enhances lipid biosynthesis and accelerates the pro-
gression of atherosclerosis. Of clinical interest is the observation thatmultiple regression analysis demonstrated that the tissue ET-1 level is
the main predicting factor of atherosclerosis progression in patients
with chronic kidney disease (Noshad et al., 2009).
In addition, the expression of big ET-1 and ECE-1 is increased in
atherosclerotic arteries (Bacon et al., 1996; Maguire and Davenport,
1998). ECE-1 was demonstrated to be localized to endothelial cells,
vascular smooth muscle cells of the media, macrophages as well to
the ﬁbrous cap of atherosclerotic lesions (Böhm et al., 2002c; Ihling
et al., 2001). The functional relevance of increased expression of
ECE-1 in atherosclerotic arteries was investigated by determination
of formation and activity of ET-1 in patients with atherosclerosis. Ad-
ministration of big ET-1 resulted in more pronounced forearm vaso-
constriction in patients with atherosclerosis than in age-matched
controls (Böhm et al., 2002c) as well as increased local formation of
ET-1. These observations suggest that the increased expression of
ECE-1 translates into increased formation of ET-1 and increased vas-
cular tone in patients with atherosclerosis.
Altered expression of ET receptors in atherosclerosis has also been
described. An increased number of ETB receptors were demonstrated
in human atherosclerotic arteries (Iwasa et al., 1999). The expression
was localized to inﬂammatory cells (macrophages, T-lymphocytes)
and vascular smoothmuscle cells. It was suggested that foamymacro-
phages and T-lymphocytes modulate a switch in expression from ETA
to ETB receptors on vascular smooth muscle cells which may be of im-
portance for the progression of atherosclerosis (Iwasa et al., 1999). In
addition, both ETA and ETB receptor expression were increased in in-
ternal mammary arteries from patients with coronary artery disease
(Sutherland et al., 2006). Not only receptor protein expression but
also total ET-1 binding capacity for ET-1 has been described to be
increased in atherosclerotic blood vessels from (apoE−/−) micemainly
due to increased binding to the ETA receptor (Barton et al., 1998). As
illustrated in Fig. 1, available data demonstrate important alterations
in the expression of ET-1 and its receptors that translate into functional
involvement of ET-1 in the regulation of vascular function and
progression of atherosclerosis (see below).
Hypercholesterolaemia
Hypercholesterolaemia, which is considered as the key risk factor for
the development of atherosclerosis, is associated with early impairment
of endothelium-dependent vasodilatation (Celermajer et al., 1994). It is
also associated with elevated plasma and tissue ET-1 concentrations,
which may account for the vasomotor dysfunction under this condition
(Lerman et al., 1993). Accordingly, inhibition of either ETA or both ETA
and ETB receptors restored endothelium-dependent vasodilatation and
NO production in hypercholesterolaemic pigs (Best et al., 1999) via a
mechanism related to increased activity of endothelial NO synthase
(eNOS). The effect on NO production induced by dual ETA/ETB blockade
was signiﬁcantly greater than that following selective ETA antagonism
(Taner et al., 2001).
There also seems to exist important interactions between oxidized
low-density lipoprotein (LDL) and ET-1 of importance in atherogenesis.
Oxidized and native LDL stimulates the production of ET-1 (Niemann et
al., 2005). Conversely, ET-1 stimulates the uptake of oxidized LDL in en-
dothelial cells via stimulation of the oxidized LDL receptor LOX-1medi-
ated by the ETB receptor (Morawietz et al., 2001). Furthermore, ET-1
activates ETA receptors on human vascular smooth muscle cells to
yield proteoglycans with increased binding to LDL (Ballinger et al.,
2009). Reduction in plasma LDL cholesterol by statins has been demon-
strated to decrease the expression of pre-pro ET-1mRNA in endothelial
cells (Hernandez-Perera et al., 1998) as well as the vasoconstrictor re-
sponse to ET-1 (Mraiche et al., 2005). Previous in vitro studies indicate
that lipid-lowering treatment suppresses the expression of ET-1 in en-
dothelial cells (Rosenson, 2001) thereby attenuating the negative effect
of ET-1 on endothelial function. Furthermore, cholesterol-lowering ther-
apy by statins further improves the beneﬁcial effects of ET antagonism
Fig. 1. Schematic ﬁgure illustrating the biological role of ET-1 in atherosclerosis and diabetes mellitus. ET-1 is under these pathophysiological situations expressed in several cell types in-
cluding endothelial cells, vascular smooth muscle cells, macrophages (M) and adipocytes. ET-1 mediates vasoconstriction via activation of both ETA and ETB receptors on vascular smooth
muscle cells and vasodilatation via stimulation of ETB receptors and release of nitric oxide (NO) from endothelial cells. ET-1may exert both inhibitory and stimulatory effects of endothelial
NO synthase (eNOS). Additional effects of ET-1 are stimulation of vascular smooth muscle proliferation, activation of macrophages-induced cytokine production, and stimulation of super-
oxide production. ET-1 inhibits insulin-stimulated glucose uptake in skeletal muscle cells and adipocytes via speciﬁc receptor-dependent mechanisms at several steps down-stream of the
insulin receptor (IR) and by interfering with GLUT 4 translocation. Additional effects of ET-1 in adipocytes are stimulation of lipolysis, release of free fatty acids (FFA) and pro-inﬂammatory
cytokines like interleukin-6 (IL-6). Collectively, the effects of ET-1 result in increased vasoconstrictor tone, impaired endothelial function, oxidative stress, inﬂammation and insulin resis-
tance. Additional abbreviations: IRS1, insulin receptor substrate 1; PI3-K; phosphatidylinositol 3-kinase, PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3,4,5-tri-
sphosphate; PDK, PIP3-dependent kinase; F-actin, ﬁlamentous actin; RIP140, nuclear receptor interacting protein 140. See text for further details and references.
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(Barton and Kiowski, 2001; Leslie et al., 2004). In a clinical study on pa-
tientswith coronary artery disease and type 2 diabetes, dual ETA/ETB re-
ceptor blockade improved endothelium-dependent vasodilatation both
before and following high dose statin therapy, suggesting that ET recep-
tor blockade exerts beneﬁcial effects on top of aggressive lipid lowering
therapy (Settergren et al., 2008a). Collectively, these observations imply
additive effect of statin therapy and ET receptor blockade on endothelial
function in patients with hypercholesterolaemia and coronary artery
disease.Pro-inﬂammatory effects
Apart from its direct vasomotor activity, ET-1 has been implicated
in inﬂammatory processes within the vascular wall. Speciﬁcally, ET-1
activates macrophages, resulting in the release of pro-inﬂammatory
and chemotactic mediators, including tumor necrosis factor (TNF)-
α, interleukin (IL)-1, IL-6 and IL-8 (Browatzki et al., 2000; Hofman
et al., 1998; Ruetten and Thiemermann, 1997). Cardiac overexpres-
sion of ET-1 in mice is associated with an inﬂammatory response in-
volving increased activation of the pro-inﬂammatory transcription
factor NF-κB and expression of several pro-inﬂammatory cytokines
including TNF-α, IL-1 and IL-6 (Yang et al., 2004). In turn, transcrip-
tion factors and pro-inﬂammatory cytokines such as NF-κB, TNF-α,
and IL-6 stimulate ET-1 production (Virdis and Schiffrin, 2003). ET-1
enhances the expression of adhesion molecules on TNF-α stimulated
vascular endothelial cells (Ishizuka et al., 1999) suggesting involve-
ment of ETB receptors. Further, ET-1 stimulates aggregation of poly-
morphonuclear neutrophils (Gomez-Garre et al., 1992). Conversely,
ET receptor blockade attenuates the accumulation of neutrophils
and myeloperoxidase activity in the ischemic myocardium (Gononet al., 2001). Although not a true atherosclerosis model, it has been
shown that vascular inﬂammation and neointima formation follow-
ing vascular injury by carotid artery ligation is attenuated in endothe-
lial cell ET-1 knockout mice (Anggrahini et al., 2009).
IL-6 has been implicated in the development of atherosclerosis
(Libby, 2002) and endothelial dysfunction in humans (Brull et al.,
2002). As noted above, ET-1 stimulates IL-6 release in vitro (Browatzki
et al., 2000) and in vivo (Böhm et al., 2007). The release of IL-6 induced
by ET-1 from human vascular smooth muscle involves activation of NF-
κB (Browatzki et al., 2000). Possibly, release of IL-6may further increase
oxidative stress as suggested by the in vitro observation that IL-6 in-
duces production of reactive oxygen species (Wassmann et al., 2004).Increased oxidative stress
Several reports support a role for ET-1 in the formation of reactive
oxygen species (ROS). Formation of superoxide (O2−) will result in de-
creased bioactivity of NO and formation of peroxynitrite. ET-1 stimu-
lates ROS production in human endothelial and vascular smooth
muscle cell cultures (Dong et al., 2005; Duerrschmidt et al., 2000),
as well as in isolated vessels (Galle et al., 2000; Loomis et al., 2005;
Lopez-Sepulveda et al., 2010). Mainly ETA receptors seem to mediate
ROS production stimulated by ET-1 although ETB receptors have been
suggested to contribute to O2- production (Dong et al., 2005;
Duerrschmidt et al., 2000). ET-1 has been shown to increase the ex-
pression of NOX2, the rate-limiting subunit of NADPH oxidase
(Mohazzab et al., 1994). The stimulating effect of ET-1 on O2- produc-
tion may also be coupled to the NADPH oxidase subunit p22phox
(Kamata et al., 2004; Kanie and Kamata, 2002). These data are in
agreement with the in vivo observations in transgenic mice overex-
pressing ET-1 (Amiri et al., 2004). These mice exhibit endothelial
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sion of NOX2. A recent report shows that ET-1 increases expression
and activity of p47phox in rat aortic rings via the ETA receptor which
would suggest that ET-1 is involved in the activation of NADPH oxi-
dase (Romero et al., 2010). It was recently demonstrated that the se-
lective ETA antagonist avosentan signiﬁcantly reduces aortic plaque
formation in diabetic apoE−/− mice, independently of effects on
blood pressure, lipid or glucose levels. The anti-atherosclerotic effect
of avosentan was associated with a signiﬁcant reduction in macro-
phage inﬁltration and reduced nitrotyrosine levels, reﬂecting a paral-
lel decrease in oxidative stress and atherosclerosis (Watson et al.,
2010). This observation supports the notion that ET-1-mediated stim-
ulation of oxidative stress is of importance although the link between
increased oxidative stress and atherosclerosis is complex as exempli-
ﬁed by the observation that genetic deletion of p47phox, an essential
component of NADPH oxidase, did not affect the progression of ath-
erosclerosis in apoE−/− mouse model (Hsich et al., 2000). On the
other hand, O2− generation may increase atherosclerosis by activating
mitogenic signalling pathways in vascular smooth muscle cells
(Vendrov et al., 2007).
The vasoconstrictor effects of ET-1 may be more pronounced in
states of reduced bioavailability of the eNOS co-factor tetrahydrobiop-
terin (BH4) (Verma et al., 2001a). Recent data demonstrate that ET-1
mediates O2− production and vasoconstriction through activation of
NADPH oxidase and uncoupled NOS in the rat aorta (Loomis et al.,
2005). The uncoupling of NOS means that NOS generates O2- instead
of NO in states of BH4 deﬁciency. These effects could be inhibited by
BH4 and by dual ET receptor blockade, but not by selective ETA recep-
tor blockade (Loomis et al., 2005). ET-1 may also promote BH4 deﬁ-
ciency in a rat model of hypertension via an ETA-mediated NADPH
oxidase pathway which contributes to impaired endothelium-
dependent relaxation (Zheng et al., 2003).
ET-1 has been demonstrated to be associated with increased oxi-
dative stress and endothelial dysfunction in humans. ET-1 mediates
a marked increase in O2- production in internal mammary arteries
and saphenous veins from patients with coronary artery disease via
a mechanism involving a ﬂavin-dependent enzyme which is likely
to be NADPH oxidase also in humans (Cerrato et al., 2010). ET-1
also stimulates O2- formation and impairs endothelium-dependent va-
sodilatation in human venous bypass conduits from patients with
coronary artery disease and diabetes (Ergul et al., 2005). The impair-
ment in endothelium-dependent vasodilatation in vivo induced by
ET-1 in healthy humans can be prevented by administration of the
anti-oxidant vitamin C (Böhm et al., 2007). Conversely, ET-1 is in-
creased in human coronary artery disease by oxygen-derived radicals
ex vivo and in vivo (Knappe et al., 2007), indicating a vicious circle of
oxidative stress leading to increased expression of ET-1 which in turn
increases oxidative stress. Taken together, these data suggest that in-
creased oxidative stress induced by ET-1 in the vessel wall contrib-
utes to endothelial dysfunction that together with pro-inﬂammatory
effects may be important mechanisms behind development of
atherosclerosis.
Interventional studies with ET receptor antagonists
Kowala et al. (1995) demonstrated that an ETA receptor antagonist
inhibited monocyte inﬁltration and development of fatty streak in
hypercholesterolaemic hamsters. Barton and co-workers demonstrat-
ed in apoE−/− mice that ETA antagonism improves endothelium-
dependent, NO-mediated relaxation and reduces atherosclerosis,
which occurred concomitantly with a reduction in tissue ET-1 con-
centrations (Barton et al., 1998). A dual ETA/ETB receptor antagonist
reduced foam cell formation in macrophages exposed to oxidized
LDL (Babaei et al., 2000). In the same study, the ET receptor antago-
nist signiﬁcantly inhibited the development of atherosclerosis in
LDL receptor knockout mice. In addition, dual ETA/ETB receptorblockade attenuated angiotensin II-induced atherosclerosis develop-
ment in apoE−/− mice without affecting blood pressure (Suen et al.,
2011). Selective ETA receptor blockade was demonstrated to reduce
diabetes-associated aortic atherosclerotic burden, macrophage inﬁl-
tration and nitrotyrosine staining in apoE−/− mice (Watson et al.,
2010). Also, selective ETA receptor blockade ameliorated vascular ste-
nosis in a mouse model of vascular remodelling following blood ﬂow
cessation (Murakoshi et al., 2002). These data clearly suggest that ET-
1 is involved in the development of atherosclerosis and that ET recep-
tor blockade exerts anti-atherogenic effects.
The observations in experimental models have led to clinical stud-
ies using ET receptor antagonists in atherosclerosis. These studies are
summarized in Table 1. Cardillo and co-workers showed that BQ123
induced a signiﬁcant increase in forearm blood ﬂow in patients with
hypercholesterolemia compared to normal subjects (Cardillo et al.,
2000) supporting the notion that risk factors for cardiovascular dis-
ease stimulate the ET system in vivo. The increase in forearm vasodi-
latation in response to BQ123 was attenuated by inhibition of NO
generation (Verhaar et al., 1998) indicating that the effect to a
major part is dependent on increased NO availability. In support of
this, BQ123 improved endothelium-dependent vasodilatation in pa-
tients with atherosclerosis (Böhm et al., 2002b). In another study,
dual ETA/ETB receptor blockade evoked greater increase in forearm
blood ﬂow in patients with atherosclerosis than in controls indicating
enhanced vasoconstrictor tone mediated by ET-1 (Böhm et al.,
2002a). Furthermore, the vasodilator response to dual ETA/ETB recep-
tor blockade was greater than that induced by selective ETA receptor
blockade in patients with atherosclerosis, whereas the opposite was
observed in control subjects. Dual ETA/ETB receptor antagonism im-
proves forearm endothelium-dependent vasodilatation in patients
with atherosclerosis (Böhm et al., 2005a). These observations may
appear surprising considering the notion that ETB receptors mediate
release of NO and induces vasodilatation. However, this highlights
the change in functional response mediated by ETB receptor from
healthy conditions under which endothelial ETB receptors cause dila-
tation via NO release to the situation in atherosclerosis with increased
number of vascular smooth muscle cell ETB receptors (Iwasa et al.,
1999) mediating vasoconstriction. This suggests that antagonizing
both receptors may be important to achieve maximal beneﬁcial vas-
cular effect in patients with atherosclerosis.
Studies focusing on the coronary circulation have been performed.
Selective ETA receptor blockade increases coronary artery diameter
and endothelium-dependent vasodilatation (Halcox et al., 2001;
Kinlay et al., 2001) in patients with atherosclerosis. Coronary dilata-
tion was more pronounced in severely stenotic than in angiographical-
ly normal segments (Kinlay et al., 2001). In line with this, dual ETA/ETB
receptor blockade dilates coronary conduit and resistance vessels and
improves coronary endothelial function of the epicardial coronary ar-
teries (Böhm et al., 2008; Halcox et al., 2007). In internal mammary ar-
teries obtained from patients undergoing coronary artery bypass graft
surgery, selective ETA blockade, selective ETB blockade, as well as dual
ETA/ETB receptor blockade improved endothelium-dependent vasodi-
latation (Verma et al., 2001b). The efﬁcacy and safety of 6 months
oral treatment with the ETA receptor antagonist atrasentan has been
evaluated in patients with coronary artery disease (Raichlin et al.,
2008; Reriani et al., 2010). Atrasentan treatment reduced blood pres-
sure and improved coronary microvascular endothelial function. Col-
lectively, these observations suggest that ET-1 is of importance for
the regulation of basal coronary vascular tone and endothelial function
in patients with coronary artery disease and that ET receptor antago-
nism improves peripheral and coronary endothelial function in these
patients. Moreover, data obtained in a clinical study (Böhm et al.,
2005a), supported by observations in vitro (Ko et al., 2002) suggest
that ET receptor antagonism exerts additional beneﬁcial effects on
endothelial function beyond that of ACE inhibitors in patients with
atherosclerosis.
Table 1
Interventional studies with ET receptor antagonists in patients with atherosclerosis and diabetes mellitus.
Reference Patients, n Intervention Main outcome
Cardillo et al.
(2000)
Hypercholesterolemia, n=12 BQ123 intra-brachially Increased forearm blood ﬂow
Kinlay et al.
(2001)
Coronary artery disease, n=8 BQ123 intra-coronary Increased coronary artery diameter, especially in stenotic areas
Halcox et al.
(2001)
Coronary artery disease, n=44 BQ123 intra-coronary Improved coronary endothelial function and increased blood ﬂow
Böhm et al.
(2002a)
Atherosclerosis, n=10 BQ123+BQ788 intra-brachially Increased forearm blood ﬂow more than with BQ123 alone
Böhm et al.
(2002b)
Atherosclerosis, n=10 BQ123 intra-brachially Improved forearm endothelial function and increased blood ﬂow
Böhm et al.
(2005a)
Atherosclerosis, n=37 BQ123+BQ788 intra-brachially Improved forearm endothelial function and increased blood ﬂow
Halcox et al.
(2007)
Coronary artery disease, n=39 BQ123+BQ788 intra-coronary Improved coronary endothelial function and increased blood ﬂow
Settergren et al.
(2008a)
Type 2 diabetes and atherosclerosis, n=39 BQ123+BQ788 intra-bracially Improved forearm endothelial+vascular smooth muscle cell
function
Böhm et al.
(2008)
Coronary artery disease, n=10 BQ123 +/−BQ788 intra-coronary Improved coronary endothelial function and increased blood ﬂow
Raichlin et al.
(2008)
Multiple cardiovascular risk factors, n=72 Oral atrasentan for 6 months Reduction in blood pressure
Reriani et al.
(2010)
Multiple cardiovascular risk factors, n=47 Oral atrasentan for 6 months Improved coronary microvascular endothelial function
Adlbrecht et al.
(2010)
Acute ST-elevation myocardial infarction,
n=28
BQ123 intra-venously Reduced enzymatic infarct size
Cardillo et al.
(2002)
Type 2 diabetes, n=15 BQ123 intra-brachially Increased forearm blood ﬂow
Shemyakin et al.
(2006)
Insulin resistance, n=12 BQ123+BQ788 intra-brachially Improved forearm endothelial function
Ahlborg et al.
(2007)
Obesity, insulin resistance and coronary artery
disease, n=7
BQ123+BQ788 intra-venously during
hyperinsulinaemic–euglycaemic clamp
Increased insulin sensitivity
Lteif et al.
(2007)
Obesity and insulin resistance, n=7 BQ123 into the femoral artery Increased insulin-stimulated leg glucose uptake
Settergren et al.
(2008b)
Type 2 diabetes with albuminuria, n=10 BQ123 intra-brachially Increased nutritive skin capillary circulation
Kalani et al.
(2008)
Type 2 diabetes and critical limb ischemia,
n=6
BQ123 into the femoral artery Increased transcutaneous oxygen tension and toe blood pressure
Shemyakin et al.
(2010)
Insulin resistance, n=11 BQ123+BQ788 intra-brachially Increased forearm glucose uptake and insulin-mediated glucose
uptake
Mann et al.
(2010)
Type 2 diabetes and overt nephropathy,
n=1392
Oral avosentan for 4 months Reduction in albuminuria, but induction of ﬂuid overload
Kohan et al.
(2011)
Type 2 diabetes and nephropathy, n=89 Oral atrasentan for 8 weeks Reduction in albuminuria
Rafnsson et al.
(2012)
Type 2 diabetes and microalbuminuria, n=46 Oral bosentan for 4 weeks Improved peripheral endothelial function
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following an episode of ischaemia (Lefer and Lefer, 1996). Ischaemia–
reperfusion injury is at least partially related to impaired availability
of endothelium-derived NO (Lefer and Lefer, 1996). Previous studies
on experimental animal models have demonstrated that ET receptor
antagonists ameliorate myocardial ischaemia–reperfusion injury by
reducing infarct size and improving post-ischaemic endothelium-
dependent vasodilatation (Pernow and Wang, 1997). The mechanism
behind the contribution of ET-1 to ischemia–reperfusion injury may
be related to increased coronary vasoconstrictor effect of ET-1 (Climent
et al., 2005), increased accumulation of neutropils in the reperfusedmyo-
cardium (Gonon et al., 2004), reduced expression of endothelial NO
synthase (Gonon et al., 2004) and production of ROS. The effect of the
dual ETA/ETB receptor antagonist bosentan was tested in a human
model of ischaemia–reperfusion injury in the forearm. Itwas demonstrat-
ed that administration of bosentan inhibited the development of endo-
thelial dysfunction following 20 min of forearm ischaemia (Böhm et al.,
2005b). Adlbrecht et al. (2010) recently presented data suggesting that
intravenous infusion of the ETA receptor antagonist BQ123 reduces the
enzymatic infarct size inpatientswithposteriorwall ST elevationmyocar-
dial infarction. This clinical observation supports previous data obtained
in experimental studies and clearly underlines the need for additional
clinical studies evaluating the efﬁcacy of ET receptor blockade onmyocar-
dial reperfusion injury in patients with ST elevationmyocardial infarction
in connection with primary percutaneous intervention.Diabetes mellitus
Type-2 diabetes mellitus is associated with micro- and macrovas-
cular complications leading to late diabetic complications including
retinopathy, nephropathy, neuropathy, skin ulcers, coronary artery
disease and peripheral artery disease. The aetiology behind vascular
complications associated with diabetes is multifactorial including im-
pairment of endothelial function with reduced bioavailability of NO,
increased oxidative stress and production of advanced glycosylated
end products (Jansson, 2007; Kim et al., 2006; Mather et al., 2001).
Endothelial dysfunction is an early ﬁnding in insulin resistance and
diabetes. It has been demonstrated that increased vasoconstrictor re-
sponsiveness due to diminished NO signaling in skeletal muscle arte-
rioles precede the development of diabetes and hypertension in a rat
model of type 2 diabetes (Lesniewski et al., 2008). Data suggesting
that that ET-1 may be of importance both for vascular dysfunction
and the dysregulation of glucose metabolism in insulin-resistant
states and type 2 diabetes is discussed below.
Molecular interactions between ET-1 and insulin in diabetes and obesity
Insulin and its intracellular signaling pathway is a key mediator in
insulin resistance and diabetes. Under physiological conditions insulin
will stimulate phosphatidylinositol 3-kinase (PI3-K) pathway, involving
phosphorylation of the serine/threonine kinase Akt, which results in
512 J. Pernow et al. / Life Sciences 91 (2012) 507–516translocation of GLUT4 transporters and stimulation of glucose uptake
(Huang et al., 2005). Phosphorylation of Akt will also directly activate
eNOS leading to enhanced production of NO (Dimmeler et al., 1999;
Fulton et al., 1999), tomaintain normal endothelial function. These vascu-
lar actions also augment the delivery of insulin and glucose to skeletal
muscle, thereby enhancing glucose uptake and utilization (Baron et al.,
1995). In insulin resistance states and type-2 diabetes mellitus insulin
will activate alternative signaling pathways including MAPK (Gogg et
al., 2009), which besides stimulating cell growth and proliferation, also
stimulates the production of ET-1 (Potenza et al., 2005). Via this mecha-
nism the pathophysiological role of ET-1will be enhanced in insulin resis-
tance and type-2 diabetes (Jansson, 2007). Early clinical observations and
experimental animal studies have revealed that plasma levels of ET-1 are
increased in insulin resistance and type-2 diabetes (Ferri et al., 1995a,
1995b; Takahashi et al., 1990). It has also been demonstrated that plasma
levels of ET-1 in type-2 diabetes correlate to impaired glucose uptake,
HbA1c levels, microalbuminuria and retinopathy (Collier et al., 1992;
Ferri et al., 1995b; Kawamura et al., 1992). The expression of vascular
ET-1 and both ETA and ETB receptors is increased in various experimental
models of diabetes (Kelly-Cobbs et al., 2011; Matsumoto et al., 2004).
Thereby, ET-1 contributes to arterial hyper-reactivity, impaired endothe-
lial function and remodeling in animal models of diabetes (Ergul, 2011).
Obesity is one of the major risk factors for the development of in-
sulin resistance, diabetes and cardiovascular disease. ET-1 plasma
levels are increased in obese patients with the metabolic syndrome
(Ferri et al., 1997). It has been demonstrated that adipose tissue re-
leases ET-1 and expresses both ETA and ETB receptors and that the ex-
pression of ETA receptor and release of ET-1 is markedly increased in
obesity (Eriksson et al., 2009; van Harmelen et al., 2008). Chronic ex-
posure of adypocytes to ET-1 leads to the insulin receptor desensitiza-
tion and decreases glucose transport through IRS-1/PI3-K/Akt
signaling pathway and this effect is reversed by ETA receptor blockade
(Ishibashi et al., 2001). ET-1 also stimulates IL-6 secretion from adipo-
cytes (Chai et al., 2009) indicating that IL-6 may mediate the effect of
ET-1 on insulin resistance. In addition ET-1 stimulates leptin produc-
tion in adipocytes (Xiong et al., 2001), indicating that ET-1 through
leptin may affect body fat stores and feeding behavior. Furthermore,
long-term incubation of adipocytes with ET-1 leads to the increased
lipolysis via the ETA receptor pathway resulting in increased free
fatty acid release (Eriksson et al., 2009). The authors showed that
ET-1 attenuates the anti-lipolytic effect of insulin by decreasing the
expression of insulin receptor, IRS-1 and phosphodiesterase-3B
through the ETB receptor pathway (van Harmelen et al., 2008).
These observations suggest that ET-1 could be a link between obesity,
insulin resistance and cardiovascular disease (Fig. 1).
ET-1 and vascular dysfunction in insulin resistance and type-2 diabetes
The vasoconstrictor tone of ET-1 is enhanced in patients with
type-2 diabetes via an ETA receptor-mediated effect (Cardillo et al.,Fig. 2. Effect of ETA receptor blockade (BQ123) on resting capillary blood cell velocity (CBV)
non-diabetic controls. Data are depicted as mean and SEM. Signiﬁcant differences between g
Modiﬁed from (Settergren et al., 2008b).2002). ET-1 also seems to contribute to endothelial dysfunction ob-
served in subjects with insulin resistance and patients with type-2 di-
abetes. Administration of ET-1 induced a marked reduction in
endothelium-dependent vasodilatation in subjects with insulin resis-
tance (Shemyakin et al., 2011). The role of endogenous ET-1 has been
evaluated by infusion of ET receptor antagonists both in subjects with
insulin resistance and patients with type-2 diabetes (Settergren et al.,
2008a; Shemyakin et al., 2006). In both these groups dual ET receptor
blockade improved endothelium-dependent vasodilatation. In pa-
tients with type 2 diabetes also endothelium-independent vasodilata-
tion was slightly but signiﬁcantly improved by dual ET receptor
blockade. This observation suggests that not only endothelial function
but also smooth muscle cell relaxation is impaired in insulin resistant
states. In one study the effect of dual ETA/ETB receptor blockade and
selective ETA receptor blockade on endothelial function was com-
pared in subjects with insulin resistance. It was found that only dual
ETA/ETB receptor blockade, but not selective ETA receptor blockade,
improved endothelium-dependent vasodilatation (Shemyakin et al.,
2006). This may imply that in this group of subjects dual ETA/ETB re-
ceptor blockade is more beneﬁcial than selective ETA receptor block-
ade. This observation may appear surprising, since ETB receptors are
known to stimulate NO release and blockade of this receptor would
be expected to impair endothelium-dependent vasodilatation. How-
ever, it has been demonstrated that vascular smooth muscle cell ETB
receptors are increased in diabetes (Ergul, 2011; Kelly-Cobbs et al.,
2011) and that ETB receptor activation stimulates production of re-
active oxygen species. Thus, there are data supporting that the ETB re-
ceptor under pathophysiological conditions may evoke effects that
resemble those mediated by the ETA receptor. Under these conditions
dual ETA/ETB receptor blockade may be more beneﬁcial than selective
ETA receptor blockade and illustrates the important difference in the
functional responses evoked by ET receptor stimulation and blockade
between physiological and pathophysiological conditions
Another important feature of type-2 diabetes is occurrence ofmicro-
vascular dysfunction. The role of ET-1 for regulation of microvascular
function in patients with type-2 diabetes has been investigated by de-
termination of cutaneous nutritive capillary function of the nail fold
(Settergren et al., 2008b). Intra-arterial infusion of the ETA receptor an-
tagonist BQ123 induced a signiﬁcant increase in baseline and peak cap-
illary blood velocity in patients with type-2 diabetes, whereas no effect
was observed in non-diabetic controls (Fig. 2). This suggests an impor-
tant role for ET-1 in regulation of microvascular function in patients
with type-2 diabetes and that ETA receptor blockade markedly im-
proves microvascular function and perfusion. This study also illustrates
the important difference regarding the functional role of the ET-system
in patients with developed cardiovascular disease in comparison with
non-diabetic patients. A subsequent pilot study also suggests a beneﬁ-
cial effect of ET-receptor blockade on transcutaneous oxygen tension
and toe blood pressure in patients with type-2 diabetes and a critical
limb ischemia (Kalani et al., 2008).and peak CBV following a 1 min arterial occlusion in patients with type 2 diabetes and
roups in change in resting and peak CBV following 60 min of BQ123 infusion are shown.
Fig. 3. Effect of dual ETA/ETB receptor antagonism (ERA; BQ123 and BQ788) on basal
and insulin-stimulated glucose uptake in the forearm of subjects with insulin resis-
tance. In one protocol saline was infused followed by insulin (dashed line). In another
protocol saline infusion was followed by ERA alone and in combination with insulin
(ﬁlled line). All infusions were given into the brachial artery. Signiﬁcant difference be-
tween the entire protocols including all time points by two-way ANOVA.
Modiﬁed from Shemyakin et al. (2010).
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ade following short-term intra-arterial infusions, a recent placebo-
controlled double-blind study demonstrated that the dual ETA/ETB re-
ceptor antagonist bosentan improved peripheral endothelial function
in patients with type-2 diabetes and microangiopathy (Rafnsson et
al., 2012). The putative beneﬁcial effect of long-term efﬁcacy of ET re-
ceptor blockade on macro-and microvascular function in patients
with type-2 diabetes mellitus is of considerable interest and should
be further evaluated in additional randomized trials.
Since nephropathy is a common complication in type-2 diabetes
and diabetic nephropathy is the leading cause of chronic kidney dis-
ease the ﬁndings regarding the role of ET-1 in diabetic nephropathy
are of importance (Barton, 2010). ET receptor blockade has been
demonstrated to exert beneﬁcial effects on proteinuria in experimental
studies (Watson et al., 2010). Recent clinical studies have demon-
strated promising results. The non-selective ET receptor antagonist
avosentan reduced albuminuria when added to standard treatment
in patients with type 2 diabetes and overt nephropathy (Mann et
al., 2010). However, this study was prematurely stopped due to sig-
niﬁcant ﬂuid overload and congestive heart failure. In support of a
renoprotective effect of ET receptor blockade, Kohan et al. demon-
strated reduction in urine albumin/creatinine ratio in patients with
type 2 diabetes and nephropathy given the ETA selective antagonist
atrasentan (Kohan et al., 2011).
Effect of ET-1 on insulin sensitivity and glucose uptake
The possibility that ET-1 may be involved in the regulation of glu-
cose uptake either via direct effect on insulin signaling as described
above or via indirect effect on peripheral blood ﬂow is of interest.
Studies on experimental models have demonstrated that ET-1 in-
duces insulin resistance in isolated rat skeletal muscle and in vivo
(Wilkes et al., 2003) and in adipocytes (Ishibashi et al., 2001). It has
also been shown that ET-1 interferes with insulin signaling in adipo-
cytes and skeletal muscle by reducing IRS-1 phosphorylation, translo-
cation of GLUT4 and reduction of PI3-K (Jiang et al., 1999;
Strawbridge and Elmendorf, 2005, 2006; Wilkes et al., 2003). More-
over, vascular endothelial cell-speciﬁc ET-1 knockout mice are pro-
tected from high-salt induced insulin resistance (Iwasa et al., 2010)
as well as from the development of diabetes mellitus-induced cardiac
ﬁbrosis (Widyantoro et al., 2010). Conversely, insulin stimulates ET-1
production in endothelial cells via PI3K-glycogen synthase kinase-
3beta (GSK3beta) signaling pathway (Yang and Li, 2008). Thus,
hyperinsulinaemia observed in insulin resistance, may lead to in-
creased ET-1 production thereby creating a vicious circle.
An initial study on humans revealed that intravenous infusion of ET-1
in healthy humans evoked a reduction in insulin sensitivity determined
during a hyperinsulinaemic–euglycaemic clamp (Ottosson-Seeberger et
al., 1997). Furthermore, the ET-1 precursor, big ET-1, reduced insulin sen-
sitivity in healthy subjects via an action mediated by the ETA receptor
(Ahlborg and Lindstrom, 2002). These observations suggest that ET-1
may induce insulin resistance in humans. This was further investigated
in a study on patients with insulin resistance and coronary artery disease.
Intravenous infusion of dual ETA/ETB receptor antagonist signiﬁcantly in-
creased insulin sensitivity during a hyperinsulinaemic–euglycaemic
clamp. Selective ETA receptor blockade did not affect insulin sensitivity,
suggesting a more beneﬁcial effect of dual ETA/ETB receptor blockade in
this patient group (Ahlborg et al., 2007). In another study (Lteif et al.,
2007) described that intra-arterial infusion of an ETA selective antagonist
increased leg glucose uptake in subjects with obesity, whereas it did not
affect glucose uptake in lean controls. The effect of dual ETA/ETB receptor
blockade was not evaluated in that study. In a subsequent study per-
formed on the forearm vascular bed in subjects with insulin resistance,
it was demonstrated that intra-arterial infusion of dual ETA/ETB receptor
antagonists increased baseline and insulin-mediated glucose uptake, sug-
gesting improved insulin sensitivity in skeletal muscle tissue of theforearm (Fig. 3) (Shemyakin et al., 2010). Collectively, these observations
indicate a role for ET-1 in the regulation of skeletalmuscle glucose uptake
in humans (Fig. 1). However, the interpretation of these in vivo studies is
complicated by the fact that the interventions also induce changes in local
blood ﬂow. It is therefore difﬁcult to conclude whether ET-1 has a direct
effect on skeletal muscle glucose uptake or if the observed effects are re-
lated to changes in local bloodﬂowand insulin delivery to skeletalmuscle
tissue. Data from experimental studies of isolated skeletal muscle tissue
from rats support a direct effect of ET-1 on glucose uptake with an initial
stimulation during short-term incubation, followed by a subsequent re-
duction during a prolonged exposure (Wilkes et al., 2003). Furthermore,
recent data indicate a direct effect of ET-1 of glucose uptake in human
skeletal muscle cells. ET-1 induced an initial increase in glucose uptake
followed by reduction in glucose uptake at 24 h, which is in agreement
with the data previously acquired in animalmodel.Western blot analyses
suggest that these cells express both ETA and ETB receptors (Shemyakin et
al., 2011).
Themolecular signaling of ET-1 resulting in changes in glucose up-
take has also been investigated. In human skeletal muscle cells ET-1
induced a short-term reduction in insulin-stimulated phosphoryla-
tion of Akt (Shemyakin et al., 2011). However, the inhibition of Akt
phosphorylation was not observed at 24 h of ET-1 incubation suggest-
ing that this pathway is less likely to contribute to the observed
changes in glucose uptake. On the other hand ET-1 increased phos-
phorylation of IRS-1 at Ser636—a negative regulatory site attenuating
glucose uptake. Therefore it is tempting to speculate that phosphory-
lation of IRS at Ser636 by ET-1 contributes to reduction in glucose up-
take in skeletal muscle cells (Fig. 1). Additional pathways involved
are impaired translocation of GLUT4 via phosphatidylinositol 4,5-
bisphosphate (PIP2)-regulated cytoskeletal events (Strawbridge and
Elmendorf, 2006) and increased cytoplasmic accumulation of
RIP140 (Ho et al., 2011), which are independent of the PI3-K and
Akt pathway, and G-protein couple receptor kinase-2-mediated IRS-
1 Ser phosphorylation and degradation (Usui et al., 2005) . However,
the signaling pathway mediating insulin resistance and reduction
glucose uptake by ET-1 is far from understood and remains to be clar-
iﬁed in future studies.
Summary and conclusions
At present ET receptor antagonists are approved for the treatment
of pulmonary arterial hypertension and for the prevention of new
digital ulcers in systemic sclerosis. Accumulating evidence suggest
514 J. Pernow et al. / Life Sciences 91 (2012) 507–516that ET-1 is of pathophysiological importance in the development of
several cardiovascular diseases including atherosclerosis, ischemic
heart disease, diabetic angiopathy, diabetic nephropathy and insulin
resistance. The expression of ET-1 and its receptors are markedly
altered during disease progression resulting in increased biological
importance of the ET-1 system (Fig. 1). Results from small randomized
clinical studies support data from promising initial pilot studies. Con-
sidering the potentially important role of ET-1 in the development of
vascular dysfunction reviewed in the present article—conditions with
increased inﬂammatory activity, oxidative stress and vascular tone
such as atherosclerosis, and vascular complications in diabetes—larger
clinical trials using ET receptor antagonists are encouraged and needed.
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